How I treat triple-class refractory multiple myeloma.

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Triple-class refractory multiple myeloma (TCR MM) presents a significant therapeutic challenge with historically poor prognosis.
• Current standard therapies include immunomodulatory imide drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (MoAbs).
• Existing treatments for TCR MM show limited efficacy, with response rates around 30% and overall survival under one year.

Purpose of the Study:

• To summarize existing literature on therapeutic options for TCR MM.
• To provide guidance on selecting therapies for this heterogeneous patient group.
• To address key questions regarding treatment sequencing and comparative efficacy of novel agents.

Main Methods:

• Review of observational studies and single-arm clinical trials.
• Analysis of emerging therapies including anti-BCMA CAR T-cells, antibody-drug conjugates, XPO1 inhibitors, and bispecific T-cell engagers (TCEs).
• Consideration of agents with specific activity in patient subsets, such as venetoclax in t(11;14) MM.

Main Results:

• Several novel agents demonstrate activity in TCR MM, including anti-BCMA therapies and XPO1 inhibitors.
• Bispecific T-cell engagers (TCEs), both anti-BCMA and non-BCMA, show promise in a majority of patients.
• Specific agents like venetoclax may offer unique benefits in biologically defined subsets.

Conclusions:

• The landscape of TCR MM treatment is evolving with promising new therapeutic strategies.
• Key unanswered questions include optimal sequencing of therapies and comparative effectiveness of different anti-BCMA platforms.
• Further research is needed to establish definitive treatment guidelines for this complex patient population.